Skip to main content

Table 3 British Columbia Randomized Radiation trial, 2005 update

From: Radiation impact in breast cancer

  Hazard ratio 95% confidence interval
DFS
   All patients 0.63 0.47 to 0.83
   N1 to N3 0.64 0.42 to 0.97
   N4+ 0.59 0.38 to 0.91
SysDFS
   All patients 0.66 0.49 to 0.88
   N1 to N3 0.68 0.45 to 1.04
   N4+ 0.63 0.41 to 0.97
Overall survival
   All patients 0.73 0.55 to 0.98
   N1 to N3 0.76 0.50 to 1.15
   N4+ 0.63 0.41 to 0.97
  1. Cyclophosphamide methotrexate, 5-fluoracil + radiation versus cyclophosphamide methotrexate, 5-fluoracil alone, including all patients and involving patients with one to three axillary nodes involved (N1 to N3) and patients with four or more axillary nodes involved (N4+). DFS, first event breast cancer recurrence (or any death); SysDFS, DFS with systemic recurrence as a first event. Adapted from Ragaz and colleagues [12].